Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).
This article is the fourth of a series of articles, which focus on understanding the terminology in diagnostic reports and the limitations and advantages of certain diagnostic tests. This article is ...
Ultragenyx and Mereo Biopharma are expecting to report results from two phase 3 trials for Osteogenesis Imperfecta (OI), commonly known as brittle bone disease, at the end of 2025. Earlier in July, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results